Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of relacorilant for endogenous Cushing syndrome
MOH_2020-03-15_008769Phase 3Recruiting
- Sponsor
- Corcept Therapeutics
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of relacorilant in endogenous Cushing's syndrome, sponsored by Corcept Therapeutics. Primary endpoint: Not specified. Started Feb 2020; status: recruiting.
02
Drugs
relacorilant
03
Conditions
endogenous Cushing's syndrome
Beyond the preview
Go deeper on MOH_2020-03-15_008769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-03-15_008769.